TUMOR CELL GROWTH-INHIBITING PHARMACEUTICAL COMPOSITIONS CONTAINING PHOSPHINO-HYDROCARBON-GOLD, SILVER OR COPPER COMPLEXES

Abstract: Pharmaceutical compositions and a method for inhibit­ ing the growth of tumor cells by administering a tumor cell growth-inhabiting amount of a bis [bis (diphenyl-phosphino) hydrocarbon]-, bis [bis (diethylphosphino) hydrocarbon]-, bis [bis (diphenylphosphino-diethylphosphino) hydrocar­ bon] gold (I), silver (I) or copper (I) complex or a tris [bis (diphenylphosphino) ethanel] dicopper (I) complex to an animal afflicted with said tumor cells.

Description: TITLE TUMOR CELL GROWTH-INHIBITING PHARMACEUTICAL COMPOSITIONS CONTAINING PHOSPHINO-HYDROCARBON-GOLD, SILVER OR COPPER COMPLEXES BACRGROUND OF THE INVENTION This invention relates to novel bis[bis (diphenylphosphino)hydrocarbon]-, bis[bis(diethylphosphino) hydrocarbon]-, bis[(diphenylphosphino-diethylphosphino) hydrocarbon]gold(I), silver(I) or copper(I) complexes or tris[bis(diphenylphosphino)edhane]dicopper(I) derivatives which have tumor cell growth-inhibiting activity, novel pharmaceutical composistions containing tumor cell growthinhibiting amounts of such complexes, and a method for treating tumor cells sensitive to such complexes by administering tumor cell growth-inhibiting amounts of such complexes to a host animal afflicted by such tumor cells. As disclosed more fully below, the active ingredients are cytotoxic to mammalian cells in vitro, for example B16 melanoma cells, and tumoricidal against animal tumor cells in vivo, for example P388 leukemia and M5076 reticulum cell sarcoma in mice. Dines, Inorg. Chem., 11(12), 2949-52 (1972), discloses bis [1,2b is (diphenylphosphino)ethane]copper(I) trifluoroacetate. Cariati et al., Inorg. Chim. Acta, 1(2), 315-18-(1967) disclose bis[1,2-bis(diphenylphosphino)- ethane3 gold(I) chloride. Bates et al., Inorg. Chim. Acta, 81(2), 151-156 (1984) disclose the crystal and molecular structure of bistlt2-bis (diphenylphosphino) ethane]gold(I) chloride. Sadler et al., J. Chem. Soc., Dalton Trans., 969-974 (1984), discloses the X-ray crystal structure of bis[l,2-bis(diphenylphosphino)ethane] gold(I) hexafluoroantimonate-acetone solvate. Cariati et al-., Ohim. Ind. (Milan), 52(10), 995-998 (1970), disclose bis[1,2-bis (diphenylphosphino)ethane]gold(I) is thiocyanate. Kuhn et al., Chemiker-Zeitung, 105(3), 87-88 (1981), discloses bis [1,2-b is (diphenylphosphino) ethane] silver (I) methanesulfonate. Carty et al., Can. J. Chem., 49, 761-6 (1971), disclose bis [1,2-bis(diphenylphosphino)ethane] copper(I) nitrate. Leoni et al., J.C.S. Chem. Comm., 5, 240-241 (1983), disclose bis[1,2-bis (diphenylphosphino) ethaneXcopper(I) di [copper (mesityl)]. Marsich, et al., J. Inorg. Nucl. Chem., 34(3), 933-46 (1972), disclose dichlorotris- [1,2-bis (diphenylphosphino)ethane] dicopper(I) -bis-chloroform and ies bromo and iodo analogs. Albano, J. Chem. Soc., Dalton Trans, 1938-43 (1972) , discloses dichlorotris-[l, 2-bis (diphenyl- phosphino)ethane] dicopper(I) bis-acetone. Edwards et al., J. Chem. Soc., Dalton Trans, 637-43 (1975), disclose dis (acetato)tris [1,2-bis (diphenylphosphino)ethane] dicopper (I). Carty et al., Can. J. Chem., 49(5), 761-6 (1971), disclose bis (nitrato)tris[1,2-bis(diphenyl- phosphino)ethane3 dicopper(I). Struck et al., J. Med. Chem., 9, 414-416 (1966), disclose cytotoxic activity for l,2-bis(diphenylphosphino)ethane which is used as a starting material to prepare some of the active ingredients of the pharmaceutical compositions and methods of treatment of the subject invention. None of the aforementioned references disclose or suggest the pharmaceutical compositions or methods of treatment of the instant invention. SUMMARY OF THE INVENTION This invention relates to a compound of the formula: EMI3.1 Formula (IA) wherein R2 and R3 are the same and are phenyl, ethyl or monosubstituted phenyl wherein said substituent is halo, or R2 is ethyl when R3 is phenyl; A1 is the same and is (CH2) n or cis-CH=CH; is (CH2)n n is 2 or 3; X1 is halo, nitrato or PF6; and 6 is Au(I), Ag(I) or Cu(I); provided that when M1 is Cu(I), Rê and R are the same and are phenyl, and A1 is (CH2)2, X1 is other than halo or other than nitrato ; and further provided that when R2 and 3 1. R3 are the same and are monosubstituted phenyl, M1 is other than Cu(I); and further provided that when R2 and R are the same and are ethyl, AÚ is (CH2)2 and M1is Au (I), X1 is other than halo; and further provided that when R2 and R3 are the same and are phenyl, A1 is (CH2)2 and M1 is Au(I), X1 is other than chloro. This invention also relates to a pharmaceutical composition which comprises an effective, tumor cell growth-inhibiting amount of an active ingredient and an inert, pharmaceutically acceptable carrier or diluent, wherein said composition is useful for inhibiting the growth of animal tumor cells sensitive to the active ingredient, and wherein the active ingredient is a compound of Formula (I) or Formula (11): EMI4.1 FORMULA (I) wherein R and R' are the same and are phenyl, ethyl or monosubstituted phenyl wherein said substituent is halo, or R' is ethyl when R is phenyl; A is the same and is (CH2) or cis-CH=CH; n is 2 or 3; X is halo, nitrato or PF6; and M is Au(I), Ag(I) or Cu(I); provided that when M is Cu(I), Rand R' are the same and are phenyl, and A is (CH2)2' X is other than halo; and further provided that when R and R' are the same and are monosubstituted phenyl, M is other than Cu(I); and further provided that when R and R' are the same and are ethyl, A is (CH2)2 and M is Au(I), X is other than halo; EMI4.2 FORMULA (II) wherein W is the same and is phenyl; and X is the same and is halo or nitrato. This invention also relates to a method of inhibiting the growth of animal tumor cells sensitive to a compound of Formula (I) or Formula (II) which comprises administering to an animal afflicted with said tumor cells, an effective, tumor cell growth-inhibiting amount of a compound of Formula (I) or Formula (II). DETAILED DESCRIPTION'OF THE INVENTION One skilled in the art will recognize that all the compounds of Formula (IA) are embraced within the scope of Formula (I). All the compounds of Formula (I) and Formula (11) can be prepared by methods available to one skilled in this art. Unless otherwise indicated, all the starting mater ials necessary to prepare the compounds of Formula (I) and Formula (II) are available from commercial sources. Generally, to prepare the gold complexes of Formula (I) where X is chloro and R and R' are the same and are phenyl or ethyl, or R is ethyl provided R' is phenyl, the starting materials are the corresponding k to -bis (diphenylphosphino or diethylphosphino) or (diethylphosph ino-diphenylphosphino) hydrocarbon] bis [chlorogold(I)] complexes represented by the following general structural formula: EMI5.1 FORMULA III in which A is as defined above, M is Au(I), and R'' and R''1 are the same and are phenyl or ethyl, or '' is ethyl provided that R''' is phenyl. The gold complex of Formula (III) is reacted with the appropriate bis(a,w-diphenyl- phosphino or diethylphosphinolor (diethylphosphino diphenylphosphino)hydrocarbon compound of Formula (IV), (Rt) )2-P p A - P (R' ") FORMULA (IV) in which A, R'' and R"' are as defined above. For example, the solid metal complex of Formula (III) is added to a solution of the hydrocarbon compound of Formula (IV) in a nonreactive organic solvent, such as acetone, and the mixture maintained at room temperature for 1-2 hours. The gold complexes of Formula (III) are prepared by reaction of 1 mole equivalent of a hydrocarbon compound of Formula (IV) with 2 mole equivalents of a reduced form of chloroauric acid hydrate obtained by treatment with thiodiglycol. The necessary Formula (IV) compounds are available from commercial sources, for example1 from Strem Chemicals, Inc., Danvers, Massachusetts. Alternatively, the gold complexes of Formula (I) where X is chloro and R and R' are the same and are phenyl or ethyl, or R is ethyl provided that R' is phenyl, are prepared directly by reaction of 2 mole equivalents of a hydrocarbon compound of Formula (IV) with 1 mole equivalent of a reduced form of chloroauric acid hydrate obtained by treatment with thiodiglycol. To prepare the gold complexes of Formula (I) where X is chloro and R and R' are the same and are monohalosubstituted phenyl, the starting materials are the corresponding (a,-bis [bis (monohalosubstituted phenyl) phosphinol hydrocarbon-bisI chlorogold (I)] complexes represented by the following general structural formula: EMI7.1 FORMULA (V) wherein A is as defined above, M is Au(I), and B is halo. The gold complex of Formula (V) is reacted with the appropriate b is [ ( a (dimonohalosubs tituted-phenyl- phosphino)hydrocarbon compound of Formula (VI): EMI7.2 FORMULA (VI) wherein A and B are as defined above. For example, the dry, powdered derivative of Formula (V) is added to a solution of the appropriate Formula (VI) compound in a nonreactive organic solvent, such as acetone. The gold complexes of Formula (V) are prepared by reaction of 1 mole equivalent of the appropriate Formula (VI) compound with 2 mole equivalents of a reduced form of chloroauric acid hydrate obtained by treatment with thiodiglycol. The compounds of Formula (VI) are prepared by reacting the appropriate monohalosubstituted phenyl magnesium bromide compound with the appropriate bis (dichlorophosphino)hydrocarbon ligand, which are available from commercial sources, such as Strem Chemicals Inc., Danvers, Massachusetts. The necessary magnesium bromide compounds can be prepared by methods known to one of skill in the art, for example, by reacting the appropr ite monohalosubstituted phenyl compound with magnesium bromide. Another method which may be utilized by one of skill in'the art to prepare gold(I) compounds of Formula (III) is the method of McAnliffe et al., J.C.S. Dalton, 1730 (1979), i.e. reacting sodium tetrachloroaurate with the appropriate Formula (IV) or Formula (VI) compound. Another method which may be utilized by one of skill in the art to prepare gold(I) compounds of Formula (I) is the method of Cariati et al., Inorg. Chim. Acta, 1(2), 315-18 (1967), i.e. reacting 1 mole of a solution of hydrogen tetrachloroaurate in ethanol with two moles of the appropriate Formula (IV) or Formula (VI) compound. To prepare the gold complexes of Formula (I) where X is nitrate, the corresponding Formula (I) products where X is chloro are treated with, for example, sodium nitrate in acetone solution. To prepare the gold complexes of Formula (I) where X is hexafluorophosphate, the corresponding products where X is chloro are treated with, for example, sodium hexafluorophosphate in water solution. The silver complexes of Formula (I) wherein X is nitrato and R and R' are the same and are phenyl or ethyl, or R is ethyl provided that R' is phenyl, are similarly prepared by reaction of 2 mole equivalents of the appropriate compound of Formula (IV) with 1 mole equivalent of silver nitrate in a nonreactive organic solvent, such as acetone, at room temperature for one-half. to one hour. The silver complexes of Formula (I) wherein X is chloro and R and R' are the same and are monohalosubstituted phenyl are similarly prepared by reacting the appropriate Formula (V) compound wherein M is Ag (I) with the appropriate Formula (VI) compound. The silver complexes of Formula (V) are prepared by reacting the appropriate Formula (V') compound with silver(I) nitrate. To prepare the silver complexes of Formula (I) wherein X is chloro, the corresponding Formula (I) products where -X is nitrato are treated with, for example, sodium chloride in aqueous acetone solution. To prepare the silver complexes of Formula (I) wherein X is hexafluorophosphate, the corresponding products where X is nitrato are treated with, for example, sodium hexafluorophosphate in water solution. The copper complexes of Formula (I) wherein X is chloro and R and R' are the same and are phenyl and A is cis-CH=CH or (CH2)3r or R and R' are the same and are ethyl or R is ethyl provided that R' is phenyl and A is as defined above are similarly prepared by reacting the appropriate Formula (IV) compound with 0.5 mole equivalent of copper(I) chloride. The copper complex of Formula (II) wherein X is chloro can be prepared by reacting copper(I) chloride with 1,2-bis (diphenylphosphino)ethane, available from commercial sources such as Strem Chemicals, Inc., Danvers, Massachusetts, in chloroform. To prepare the copper complexes of Formula (I) or Formula (II) where X is nitrate, one of skill in the art may employ the method of Carty et al., Can J. Chem., 49, 761-6 (1971), i.e. reacting an excess of the appropriate Formula (IV) compound with copper (II) nitrate. To prepare the copper complexes of Formula (I) where X is hexafluorophosphate, the corresponding products where X is chloro are treated with, for example, sodium hexa-luorophosphate in water solution. As stated above, the active ingredients used herein have tumor cell-growth inhibiting activity which has been demonstrated in a variety of test systems. The B16 melanoma cell assay measures the ability of a compound to inhibit the clonogenic capacity of cells in vitro following a two-hour exposure to the compound. Initially, the cytotoxic activity of the Formula (I) and Formula (II) compounds was evaluated in vitro using B16 melanoma cells according to the following assay: B16 melanoma (highly metastatic subline, F10) are used and maintained as monolayer cultures in Minimal Essential Media (Grand Island Biological Co., Grand Island, N. Y. ) supplemented with 10% calf serum, 1% antibiotics in a 5% C02 humidified incubator at 37 C. Asynchronous populations of cells are harvested and replated to 5000 cells/plate in sterile 60 mm x 15 mm petri plates. Plates are incubated overnight to allow attachment of the cells to the plate. Cells are treated with a Formula (I) or Formula (II) compound or cisplatin under sterile conditions, allowed to react for 2 hours followed by aspiration of medium. Plates are washed one time with 5 ml of phosphate buffered saline (PBS), followed by the addition of 5 ml of fresh media. Plates are 'ncubated for 5 days at 370 in a C02 incubator. viability is measured by the ability of a cell to form a colony of greater than 50 cells. Colonies are fixed with 0.5% crystal violet in 95% ethanol. Plates are dried and counted with a Biotran III Automatic Count Totalizer (New Brunswick Scientific Co., Edison, .J.). Mean and standard deviation of triplicate samples are determined for each drug concentration. The data are analyzed by plotting the log of the survival fraction (number of colonies in drug treated plates/number of colonies in controls) versus the drug concentration. An evaluation of several compounds of Formula (I) in the in vitro B16 melanoma assay is shown in Table I. TABLE EMI11.1 Compound R R' A M X IC5n (a) Number il-IM) 1 phenyl phenyl (CH2)2 Au(I) C1 4.5 2 phenyl phenyl (CH2)2 Ag(I) N03 4 3 phenyl phenyl CH=CH Au(I) Cl 2 4 phenyl phenyl (CH2)3 Au(I) C1 0.6 a Concentration which inhibits cloning efficiency of B16 melanoma cells by 50% on a.2-hour exposure Additionally, in another in vitro assay, Compound No. 1 from Table I effectively killed HEP-29 human colon carcinoma cells following a 2-hour exposure to concentrations below the lOuM level. P388 lymphocyte leukemia is currently the most widely used animal tumor model for screening for anti tumor agents and for detailed evaluation of active compounds. This tumor system is widely accepted as an anti tumor agent screening tool because it is sensitive to virtually all of the clinically active antineoplastic agents; quantitative and reproducible; amenable for large-scale screening; and predictive for activity in other animal tumor models. Drugs that are highly active in the intraperitoneal (ip) P388 tumor model are generally active in other tumor models as well. The anti tumor activity of the compounds of Formula (I) and Formula (II) is demonstrated in the P388 leukemia mouse model employing the following protocol: 106 P388 leukemia cells are inoculated ip in B 6D2F1 mice. Twenty-four hours later, if the tumor inoculum proves to be free of bacterial contamination (as determined by 24 hours incubation in thioglycollate broth), animals are randomized into groups of 6 and housed in shoebox cages. Metal complexes are dissolved in a minimal volume of either N,N--dimethylacetamide (A) or 95% ethanol (depending upon solubility). An equal volume of saline is added; if the drug comes out of solution an equal volume of Cremophor (polyethoxylated castor oil) is added and then saline qs to a concentration such that the desired dose is delivered in 0.5 ml. The final concentration of DMA, ethanol and Cremophor is 10 percent. Dilutions for lower doses are made with saline so there is a decreasing proportion of organic solvents in the vehicle with decreasing dosage. These vehicles provide soluble formulations (or suspensions). Formulations are prepared immediately prior to injection. The Formula (I) and Formula (II) compounds are administered ip on Days 1 through 5 (i.e. treatment is initiated 24 hrs after tumor inoculation). Each experiment includes three groups of 6 animals as untreated controls and animals treated with a positive control, cisplatin, at two dose levels. Animals are weighed as a group on Days 1, 5 and 9 and average weight change (a wt.) is used as a reflection of toxicity. Each experiment also includes an inoculum titration -- groups of 8 mice inoculated ip with 105 to 100 P388 leukemia cells. The titration is used to calculate cell kill achieved by treatment with drugs. Animals are monitored daily for mortality and experiments are terminated after 45 days. The endpoint is median survival time (MST) and increase in lifespan (ILS) which is the percentage of increase in MST relative to untreated controls. Untreated controls inoculated ip with 106 P388 leukemia cells generally survive for a median of 10 or 11 days. A drug is considered active if it produces > 25 percent ILS. A summary of an evaluation of the Formula (I) compounds in the in vivo P388 leukemia model is shown in Table II. TABLE II EMI14.1 Compound R A X M MTD(a) ILS max (b) Number ¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯ A (mg/k) 1 phenyl phenyl (CH2)2 Cl Au(I) 3 8625(c) 2 phenyl pnenyl (CH2)2 N03 Ag(I) 3 89/90(d) 3 phenyl pnenyl cis-CH=CH Cl Au(I) 1.5 116/80/68 4 phenyl phenyl (CH2)3 Cl Au(I) 3 84/120/64 5 phenyl phenyl (CH2)2 NO3 Au(I) 3 115/70 6 p-fluoro p-fluoro (CH2)2 C1 Au(I) 3 55/50 phenyl phenyl 22 7 m-fluoro m-fluoro (CH2)2 Cl Au(I) 12 45/55 phenyl phenyl 22 8 phenyl ethyl (CH2)2 C1 Au(t) 3 60/75 9 phenyl ethyl (CH2)2 C1 Cu(I) 1.S 48/45 10 ethyl ethyl (CH2)2 PF6 Au(I) 4 40/30 11 ethyl ethyl (CH2)2 NO3 A9(I) O.S 50/40 i2 phenyl phenyl (CH2)3 C1 Cu(I) 2 82/110/85 13 phenyl phenyl cis-CH=CH C1 Cu(I) 2 45/90/75 (a) maximally tolerated dose for 86D2F female mice on an ip qDXS regimen. (b) maximum increase in lifespan produced in mice bearing ip P388 leukemia. c) data based on 21 different experiments. ,d) figures separated by slashes represent data generated in separate experiments Additionally, the Formula (11) compound wherein X is chloro was tested twice in the ip P388 leukemia model and exhibited an ILS of 100% and 115% at a MTD of 2 mg/kg. Based on the data set forth in Tables I and II, the compounds of Formula (I) and Formula (II) showed significant cytotoxicity and anti tumor activity. In particular, the compound of Formula -(I) wherein R and R are phenyl, A is (CH2)2r M is Au (I) and X is Cl has confirmed activity in the P388 leukemia mouse assay with an ILS comparable to the clinically useful antitumor agent cisplatin. Another chemosensitive tumor model is intraperitoneally implanted M5076 reticulum cell sarcoma in mice. In this system B6D2F, female mice are inoculated with 0.5 ml of a 10 percent (w:v) brei of M5076 prepared from pooled sc tumors excised at about 21 days from C57B1/6 donors. Drugs are administered ip. Daily treatment is begun 24 hours after implantation and is continued for ten days. The treatment regimen for M5076 is more prolonged than for P388 because of the slower growth rate and longer control survival time of the M5076 tumor. Compounds of Formula (I) and Formula (II) were evaluated in this assay. An evaluation of several compounds of Formula (I) in the M5076 reticulum cell sarcoma assay at their maximally tolerated dose (MTD) is set forth in Table III. An ILS of > 25% indicates activity in this tumor model. TABLE III Compound No. (a) MTD (mg/kg) (b) ILS (max) (c) (%) 1 2 56/83/52/47 2 2 48 3 2.4 69 4 2 116 8 2 46 (a) see Table II for structures (b) maximally tolerated dose for B6D2F female mice on an ip qDX10 regimen (c) maximum increase in lifespan produced in mice bearing ip M5076 reticulum cell sarcoma (figures separated by slashes were generated in separate experiments). Additionally, the Formula (II) compound wherein X is chloro was tested in the M5076 reticulum cell sarcoma assay and exhibited an ILS of 60% at a MTD of 1.6 mg/kg. The cytotoxic activity of several Formula (I) and Formula (II) compounds was evaluated in vivo using B16 melanoma cells. In this system, groups of eight B6D2F1 mice are inoculated ip with 0.5 ml of a 10% (w:v) brei of B16 melanoma prepared from pooled Sc tumors excised at 14-21 days from C67B1/6 donor mice. Daily treatment is begun 24 hours after tumor implantation and is continued daily for ten (10) days. The route of drug administration is ip. The inice are monitored daily for survival for sixty (60) days. Antitumor activity is assessed by prolongation of median survival time. An ILS of > 25% indicates activity in this tumor model. A summary of the results of the in vivo ip B16 melanoma assay is shown in Table IV. TABLE IV Compound No. (a) MTD (mg/kg) (b) ILS (%) (c) 1 2 50/43/33 4 2 34/28 (a) see Table A for structure. (b) maximally tolerated dose for B6D2F1 mice on an ip qDxlO regimen. (c) maximum increase in lifespan produced in mice bearing ip B16 melanoma (figures separated by a slash were generated in separate experiments). Additionally, the Formula (II) compound wherein X is chloro was tested in the ip B16 melanoma assay and exhibited an ILS of 54% at a MTD of 1 mg/kg. Compound No. 1 from Table II was also tested in a further in vivo tumor model, mammary adenocarcinoma 16/c, a tumor model sensitive to DNA binders and alkylating agents. In this experiment, the tumor was implanted Sc in C3H mice, and the drug was administered ip or iv on an intermittant treatment schedule, i.e., once on days 1, 5, 9, 13 and 17. Tumors were measured 3 weeks after implantation, and activity was assessed by degree of tumor growth inhibition. Cisplatin, a drug which generally produces complete inhibition of the growth of mammary adenocarcinoma 16/c, was used as a positive control. A tumor growth inhibition of > 7596 indicates that a drug is active in this type of animal tumor model. The results of this assay are summarized in Table V. TABLE V Regimen Mean Tumor Route and Optimal Volume Schedule of Dose (mm3) inhibition Drug Administration (mg/kg) on Day 21 (%) N.P. Experiment 1 Control 1187 + 999 1/24 Cisplatin ip, q4D x 5 6 30 + 64 97 6/8 Compound (a) p, I p q4D x 5 8 96 + 143 92 4/7 Experlment 2 Control 1113 + 626 0/23 Cispiatin Ip. q40 x 5 6 0 100 8/8 iv, q40 x 5 6 21 + 61 98 7/8 Compound No. I p, q4D x 5 6 430 + 291 61 0/8 Iv, q40 x 5 12 181 + 163 84 2/8 Experiment 3 Control 936 + 353 0/24 Clsplatin Ip. q40 x 5 6 586 + 266 37 0/8 compound No. I Ip q4D x 5 8 0 IC 5/5 * - - N. P. = Proprotion of mice without palpable tumor. W Day 21 a - See Table = for structure Likewise, Compound No. 1 from Table II was tested in an additional in vivo tumor model known as ADJ-PC6 Plasmacytoma. In this assay, tumor cells are carried by serial subcutaneous (sc) passage in BALB/c female mice and then collected aseptically on ca. day 21 and minced in Hank's balanced salt solution. The cells are then dispersed by homogenization in a loose-fitting teflon glass homogenizer, and cell concentration is adjusted to 4x106 viable (trypan blue-excluding) cells per ml by hemocytometer counts. A total of 0.5 ml (2x106 cells) is implanted sc on the right flank of BALB/c female mice in groups of 8. Treatment is given ip on Days 1-10 or iv on Days 1-5, and tumors are measured in perpendicular diameters with a vernier caliper on Day 18. Tumor volume is calculated by multiplying length x width x 0.5. Generally, > 758 inhibition of tumor growth reflects significant antitumor effect. Cisplatin, the positive control compound, produces complete tumor growth inhibition. The results of this assay are summarized in Table VI. TABLE VI Dose Dosage Tumor Growth Inhibition (Day 18) (mg/kg) regimen N.P. ) I MTV O) 8 Inhibition 3 ip, qDl-1O 6/6 0 + 0 100 12 iv, qDl-5 3/6 67 + 71 89 3 ip, qDl-10 0/8 252 + 220 58 (d) - N. P. = Proportion of mice without palpable tumor on Day 18. (b) - MTV = Mean Tumor Volume (mm3) on Day 18. Additionally, Compound No. 1 from Table II was tested in another in vivo tumor model known as subcutaneous M5076 reticulum cell sarcoma in mice according to the following protocol: B6D2F1 female mice are inoculated Sc in the flank with 0.5 ml of a 10% (w:v) brie of M5076 prepared from pooled sc tumors excised at about Day 21 from C57B1/6 donors. Treatment is initiated one day after tumor implantation, and is continued daily for 10 days. Tumors are measured 21 days after tumor implantation activity is determined by the degree of tumor growth inhibition. Generally, > 75% inhibition of tumor growth reflects significant antitumor effect. Cisplatin, the positive control compound, produces complete tumor growth inhibition. The results of this assay are summarized in Table VII. TABLE VII Dose Dosage Tumor Growth Inhibition (Day 21) (mg/kg) regimen N.P. aj MTV ID) % Inhibition 2 ip, qDXlO 2/7 61 + 39 91 2 ip, qDX10 1/7 168 + 112 48 (a) - N.P. = Proportion of mice without palpable tumor on Day 21. (b) - MTV = Mean Tumor Volume (mm3) on Day 21. The pharmaceutical compositions of this invention comprise an effective tumor cell growth-inhibiting amount of a compound of Formula (I) or Formula (II), and an inert pharmaceutically acceptable carrier or diluent. These compositions are prepared in dosage unit form appropriate for parenteral administration. Compositions according to the invention for parenteral administration include sterile aqueous or nonaqueous solutions, suspensions or emulsions. The composition may be in the form of a solution of the active ingredient in a minimal volume of dimethylacetamide or ethanol, for example 5% v/v, brought up to volume with peanut oil or normal saline solution. Polyethoxylated castor oil, for example 2 to 5% v/v, may also be used to solubilize the active ingredient. In addition, the composition may be in the form of a slurry with, for example, hydroxypropyl cellulose or other suitable suspending agent. As an emulsifying agent, lecithin for example may be used. The composition may also be provided in the form of a sterile solid which can be dissolved in a sterile injectable medium immediately before use. It will be appreciated that the actual preferred dosages of the compounds of Formula (I) or Formula (II) used in the compositions of this invention will vary according to the particular complex being used, the particular composition formulated, the mode of administration and the particular site, host and disease being treated. The route of internal administration should be selected to ensure that an effective tumor cell growth inhibiting-amount of the metal complex contacts the tumor. Optimal dosages for a given set of conditions can be ascertained by those skilled in the art using conventional dosage determination tests in view of the above experimental data. For parenteral administration the dose generally employed is from about 5 mg to about 20 mg/m2 of body surface per day for one to five days, repeated about every fourth week for four courses of treatment. The method for inhibiting the growth of tumor cells sensitive to a compound of Formula (I) or Formula (II) in accordance with this invention comprises administering to a host animal afflicted with said tumor cells, an effective tumor cell growth-inhibiting amount of a compound of Formula (I) or Formula (II). As described above, during the course of treatment the active ingredient will be administered parenterally in an amount selected from about 300 mg to about 1000 mg. EXAMPLES The following examples illustrate the chemical preparation of several compounds of Formula (I) and Formula (II) used in the compositions and methods of this invention and as such are not to be construed as limiting the scope thereof. All temperatures are in degrees Centigrade. EXAMPLE 1 Bisll,2-Bis (diphenylphosphino)ethaneiGold(I) Chloride Method A Sodium chloroaurate hydrate (0.45 g, 1.1 mmol) was reduced to gold(I) by thiodiglycol (0.28 g, 2.2 mmol) in 7 ml of 2.5:1 aqueous acetone. When the solution became colorless l, -bis (diphenylphosphino)ethane (0.22 g, 0.55 mmol), obtained from Strem Chemicals, Inc., Danvers, Massachusetts, in 10 ml of acetone was added dropwise over 5 minutes. After stirring for one hour, the white solid [1,2-bis (diphenylphosphinoZethane3 bis-[chlorogoldfI)} was filtered off, washed with water and then acetone, yield 95%, melting point (m.p.) 262-267 . [1,2-Bis (diphenylphosphino)ethane] bis[chlorogold(I)] (0.89 g, 1.025 mmol), prepared as described above, was added as a solid to a solution of l,2-bis(diphenyl- phosphino)ethane (1.35 g, 3.38 mmol), obtained from Strem Chemicals, Inc., Danvers, Massachusetts, in about 25 ml of acetone. The resultant clear solution was stirred for one hour and crystals were obtained by cooling overnight at 'O A second crop of product was obtained by concentrating the solvent at room temperature, total yield 70%, m.p. 155-270 . Method B Sodium chloroaurate hydrate (0.5 g, 1.35 mmol) was reduced by thiodiglycol (0.33 g, 2.70 mmol) in aqueous acetone (2.5:1, 7 ml). The solution was cooled to 0-50 and added dropwise with stirring to a solution of 1,2-bis (diphenylphosphino)e'chane (1.07 g, 2.70 mmol), obtained from Strem Chemicals, Inc., Danvers, Massachusetts, in about 30 ml of acetone, A clear colorless solution resulted which was stirred for 30 minutes and then the solvent was concentrated to 10 ml at room temperature. The solid product was obtained by addition of water, was recrystallized from aqueous methanol, washed with cold aqueous methanol and dried in vacuo, yield 79%, m.p. between 173-277 in 3 stages. EXAMPLE 2 Bis [1,3-8is (diphenylphosphino)propane]Gold(I) Chloride Sodium chloroaurate (2 mol eq) was reduced in situ by thiodiglycol (4 mol eq) in 3:1 aqueous acetone and 1,3-bis (diphenylphosphino)propane (1 mol eq), obtained from Strem Chemicals, Inc., Danvers, Massachusetts, in a minimum volume of acetone was added dropwise to- give an immediate white precipitate, [1,3-b is (diphenylphosph ino ) propane] bis- [chlorogold(I)] . This was filtered, washed with water, then ether and dried in vacuo, yield 77%, m.p. 245-255 . Solid [1,3-bis (diphenylphosphino)propane] bis [chlorogold(I)] (140 mg, 0.16 mmol), prepared as described above, was added to a stirred solution of 1,3-bis (diphenylphosphinoApropane (198 mg, 0.48 mmol), obtained from Strem Chemicals, Inc., Danvers, Masschusetts, in 5 ml of acetone. The solid completely dissolved and a white crystalline solid immediately separated from the solution. This was filtered and washed with cold acetone and ether. A second crop was obtained by adding water to the cloud point, total yield 70%, m.p. 193-195 . EXAMPLE 3 Bis [1,2-bis (diphenylphosphino)ethane]Gold (I) Nitrate Solid [1,2-bis (diphenylphosphino)ethane]bis- [chlorogold(I)] (0.40 g, 0.46 mmol), prepared as described in Example 1, was added to a solution of bis (12-diphenylphosphino)ethane (0.55 55 g, 1.39 mmol), obtained from Strem Chemicals, Inc., Danvers, Massachusetts, in 25 ml of acetone. The resultant clear solution was stirred for 30 minutes and then sodium nitrate (0.40 g, 4.6 imnol) in 10 ml of water was added. The product was obtained as a white crystalline solid by slow evaporation of the solvent at room temperature, and was washed with water and dried in vacuo, m.p. 190.2000. EXAMPLE 4 Bis fcis-l , 2-bis (diphenylphosphino)ethylene] Gold (I) Chlor ide Sodium chloroaurate hydrate (0.5 g, 1.35 mmol) was reduced by thiodiglycol (0.33 g, 2.70 mmol) in 7 ml of 2.5:1 aqueous acetone giving a clear colorless solution. The cooled- solution "as added with stirring to a solution of cis-bis (1 ,2-dipnenylphosphino)ethylene (1.07 g, 2.7 mmol), obtained from Strem Chemicals, Inc., Danvers, Massachusetts, in 25 ml of acetone. The product crystallized from solution after reducing the volume to 10 ml, was filtered, washed thoroughly with water and then dried in vacuo, yield 88%, m.p. 226-250o EXAMPLE 5 Bis fl, 2-bis (diphenylphosphino)ethane] Silver (I) Nitrate Silver nitrate (0.10 g, 0.60 mmol) in 1 ml of water was added to a solution of 1, 2-b is (diphenyl- phosphino)ethane (0.50 g, 1.25 mmol), obtained from Strem Chemicals, Inc., Danvers, Massachusetts, in 25 ml of acetone. The clear solution was stirred for 30 minutes, the volume reduced to about 10 ml and the product precipitated by the addition of about 50 ml of water. White needles were obtained by recrystallization from acetone/water, washed with water and dried in vacuo, yield 90%, rn.p. 225-2300. EXAMPLE 6 IBis [1, 2-bis (diethylphosph ino)ethane] Silver (I) Nitrate Solid silver nitrate (0.21 g, 1.22 mmol) was added to a solution of 1,2-bis(diethylphosphino)ethane (0.51 g (0.55 ml), 2.45 mmol), obtained from Strem Chemicals, Inc., Danvers, Massachusetts, in CHCl3 (5 ml). The crystals all dissolved after a few minutes, and the clear solution was stirred for 30 minutes. The solvent was evaporated at room temperature, leaving a clear oil, then the complex was isolated as a white powder by repeated scratching in ice-cold Et2O and hexane and was dried in vacuo, yield 70%, m.p. 104-114 . EXAMPLE 7 Bis 11,2-bis (diphenylphosphino)ethane]Gold(I) Chloride Alternatively, the named product can be prepared by the method of Cariati et al., Inorg. Chim. Acta, 1(2), 315-318 (1967), according to the following procedure: A solution of hydrogen tetrachloroaurate (5.13 mmoles, 1.01 g Au) in ethanol is treated with 1,2-bis(diphenylphosphino)- ethane (10.3 mmoles, 4.10 g). The solution is then evaporated -and the residue dissolved in chloroform is precipitated by addition of n-butylether. EXAMPLE 8 Bis (I, 2-bis (diethylphosphino)ethane] Gold (I) Hexafluorophosphate Solid [1, 2-b is (diethylphosphino ) ethane] bis tchlorogold(I)], (0.53 g, 0.79 mmol) prepared as described in Example 1, was suspended in acetone (10 ml) and l,2-bis(diethylphosphino)ethane (0.54 g (0.58 ml), 2.61 mmol), obtained from Strem Chemicals, Inc., Danvers, Massachusetts, was added dropwise. After stirring for a few minutes, a clear solution was obtained. This was stirred for 30 minutes, and then NaPF6 (0.27g, 1.58 mmol) in H20 (3 ml) was added dropwise. The volume was reduced to 5 ml, and th complex obtained as a white solid after the addition of 1120 ( 25 ml), and resrystal- lization from EtOH, yield 83%, m.p. 240-255 EXAMPLE 9 Bis [ l-die thylph osph ino- ino-2-diphenylphosph ino ) ethane) Copper (I) Chloride Solid copper (I) chloride (0.081 g, 0.81 mmol) was added to a fresh solution of (l-diethylphosphino-2 diphenylphosphino)ethane (0.54 g (0.50 ml), 1.79 mmol), obtained from Strem Chemicals, Inc., Danver, Massachusetts, in CHIC13 (10 ml) in an N2 atmosphere. After stirring under a steady stream of N2 for 2 hours, all the solid had dissolved, hexane (10 ml) was added, and the solution was left at 30 for 24 hours. The solvent was decanted from the clear oily residue, and the product was obtained as a white solid after scratching the oil in ice cold acetone (1 ml) and ice cold hexane (1 ml), yield 0.42g, m.p. 112-115 . EXAMPLE 10 Bis [ (l-diethylphosph ino-2-diphenylphosphino)ethane] Gold(I) Chloride Solid [bis (l-diethylphosphino -2-diphenylphosphino)ethane] bislchlorogold (I)] (0.26 g, 0.34 mmol) prepared with (l-die th ylph osph ino-2-diphenylphosph ino) ethane substantially in accordance with the procedure described in Example 1] was added to a solution of (l-diethyl-phosphino-2-diphenylphosphino)ethane (0. 34 g, (0.31 ml) 1.12 mmol) obtained from Strem Chemicals, Inc., Danvers, Massachusetts, in CHCl3 (10 ml) giving a clear colorless solution. This was stirred for 30 minutes, and then the solvent was evaporated to dryness at room temperature giving a clear gum. The product was obtained as a white solid by scratching the gum in ice-cold Et20, .yield 90%, m.p. 170-200 . EXAMPLE 11 Tr is[l, 2-b is (diphenylphosphino ) ethane] Dicopper (I) Chloride Copper (I) chloride (0.087 g, 0.88 mmol) was added as a solid to a solution of [1,2-bis (diphenyl- phosphino)ethane] (0.88g, 2.2 mmol), obtained from Strem Chemicals, Inc., Danvers, Massachusetts, in chloroform (10 ml). After stirring for two hours under a steady stream of N2, all the solid had dissolved. The product was obtained as a white precipitate, by the addition of hexane (5 ml), on cooling to 3, and was filtered and dried in vacuo; yield 50%, m.p. 260-2700 EXAMPLE 12 Bis[1,2-bistbis (4-fluorophenyl)phosphino] ethane Gold(I) Chloride Thiodiglycol, 2.1 g (0.017 mol) was added to a stirred solution of 2.47 g (0.006 mol) of chloroauric acid in a mixture of 10 ml water and 30 ml CH30H. When a colorless solution resulted, 1.30 g (0.00276 mol) of 1,2- ethanediyl-bis[bis (4-fluorophenyl)phosphine, [prepared by reacting 1, 2-bis (dichlorophosphino)ethane, obtained from Strem Chemicals Inc., Danvers, Massachusetts, with a Grignard reagent of 4-fluorophenyl magnesium bromide in THF] in a mixture of 30 ml CHC13-30 ml CH OH was added 3 dropwise with cooling. After the addition was complete, the reaction mixture was stirred an additional 30 minutes. The product (separated solid) was removed, dried and yielded 2.55 g of r [1, 2-bis ( 4-fluor [1,2-bis[(4-fluorophenylJphosphino] ethane]bislchloro-gold(I)] with a melting point of 271-272 . Dry, powdered -[1,2-bis[(4-fluorophenyl)- phosphinoAethane]bis[chlorogold(I)] (0.561 g, 0.6 mmol), prepared as described above, was stirred into a solution containing 0.847 g (1.8 mol) of 1,2-ethanediyl-bis[bis (4-fluorophenyl)phosphine], prepared as described above, in 15 ml of acetone. The resulting solution was filtered and the filtrate concentrated under reduced pressure to an amorphous solid. Crystallization of the solid from MeOH/H2O gave 0.91 g of the named product, m.p. 229-230 . EXAMPLE 13 Bis[l,2-bis[bis (3-fluorophenyl)phosphino] ethane] Gold(I) Chloride A solution containing 2.73g (5.8 mmol) of 1,2-ethanediyl-bis [bis (3-fluc)rothenyl)phosphine3, prepared using 3-fluorophenyl magnesium bromide substantially in accordance with the procedure outlined in Example 12, in 25 ml of acetone was stirred into an ice-cooled solution of gold(I), prepared by adding 0.87 ml {8.7 mmol) of thiodiglycol to a mixture of 5 mL H20/2û ml CH3OH containing 1.196g (2.9 mmol) of chloroauric acid tetrahydrate. The semisolid residue that separated on refrigeration overnight was solidified by trituration under ether. Recrystallization from CH2C12/toluene gave 1.267g of named product, m.p. 235-245 EXAMPLE 14 Bis [ 1,3-bis (diphenylphosphino)propane]Copper (I) Chloride Copper (I) chloride (0.132 g, 1.33 mmol) was added as a solid to a solution of 1,3-bis (diphenylphosphino) propane (1.108 g, 2.68 mmol), obtained from Strem Chemicals Inc., Danvers, Massachusetts, in chloroform (ca 50 ml). After stirring for 1 hour under a steady stream of N2, the solid had dissolved, giving a yellow solution. The solvent was removed by rotary evaporation, and the oily residue was solidified by repeated trituration in ice-cold hexane (1 ml) and ice-cold diethylether (1 ml). The product was recrystallized from MeOH (3 ml) by the addition of E12O (10 ml), and was dried in vacuo; yield 60%, m.p. 90-115 . EXAMPLE 15 Bis [cis-l, 2-bis (diphenylphosph ino)e thylene3 Copper(I) Chloride Copper(I) chloride (0.078 g, 0.79 mmol) was added as a solid to a solution of [cis-1,2 bis (diphenylphosphino) ethylene] (0.66 g, 1.66 mmol), obtained from Strem Chemicals Inc., Danvers, Massachusetts, in chloroform (ca 25 ml). After stirring for 1 hour under a steady stream of N2, all the solid dissolved, giving a yellow solution. The volume was reduced to 5 ml by rotary evaporation, and white crystals formed on cooling to 00. These were filtered and recrystallized from MeOH (5 ml) after the addition of H20 (20 ml), and were dried in vacuo, yield 70%, m.p. l69l78O. EXAMPLE 16 Tris [1, 2-bis (diphenylphosphino)ethane] di copper ( Nitrate The named product can be prepared by the method of Carty et al., Can J. Chem., 49, 761-766 (1971), according to the following procedure: copper (11) nitrate is reduced by excess 1,2-b is (diphenylphosphino)ethane in hot ethanol, and then n-hexane is added which yields colorless crystals of the named product, m.p. 131-13; . EXAMPLE 17 Bis [1, 2-bis (diphenylphosphino)ethane] copper (I) Nitrate The named product can be prepared by the method of Carty et al., Can. J. Chem., 49, 761-766 (1971), according to the following procedure: the named product can be isolated from solutions of the product of Example 16 by bubbling oxygen through a refluxing ethanolic solution for 3 hours. Large crystals of the named product can be obtained on slow evaporation, m.p. 213-215 . EXAMPLE 18 Bis [1, 2-bis (diphenyl phosphino)ethanel gold (I) Bromide The named product was prepared by the method outlined in Example 1, Method B, except that 4 equivalents of sodium bromide were mixed with sodium chloroaurate hydrate in the initial water solution (5 ml). The named product was obtained in 73% yield, m.p. 182-188 . EXAMPLE 19 Bis[1,2-bis (diphenylphosphino)ethane] gold(I) Iodide The named product was prepared by the method outlined in Example 1, Method B, except that a four-fold excess of sodium iodide (in 1 ml H2O) with respect to gold was added to the solution of [1,2-b is (diphenyl phosphino)ethane] gold (I) chloride in situ before addition of H2O to precipitate the named iodide complex, m.p. 165-170 . EXAMPLE 20 As a specific embodiment of a pharmaceutical composition of this invention, an active ingredient, such as one part of the complex of Example 1, is dissolved in 5 parts of dimethylacelaide and 5 parts of polyethoxylated castor oil and then normal saline solution qs, and is administered parenterally in one dose of 5 mg/m2 to inhibit the growth of tumor cells sensitive to the active ingredient in an animal afflicted by such tumor cells.

Claims: CLAIMS (BE, CH, DE, FR, GB, IT, LI, LU, No and SE) 1. A compound of the formula (I) or (it) : EMI31.1 Formula (I) wherein R and R' are the same and are phenyl, ethyl or monosubstituted phenyl wherein said substituent is halo, or R' is ethyl when R is phenyl; A is the same and is (CH2)n or cis-CH=CH; n is 2 or 3; X is halo, nitrato or PF6; ; and M is Au(I), Ag(I) or Cu(I); provided that when M is Cu(I), R and R' are the same and are phenyl, and A is (CH2)2, X is other than halo; and further provided that when R and R' are the same and are monosubstituted phenyl, M is other than Cu(I); and further provided that when R and R' are the same and are ethyl, A is (CH2)2 and M is Au(I), X is other than halo; EMI31.2 Formula (II) wherein W is the same and is phenyl; and X is the same and is halo or nitrato for use in a method of therapy. 2. A compound according to claim 1 for use as a tumor cell growth-inhibiting agent. 3. A compound of the formula (I) EMI32.1 Formula (I) wherein R and R' are the same and are phenyl, ethyl or monosubstituted phenyl whereinsaid substituent is halo, or R' is ethyl when R is phenyl; A is the same and is (CH2)n or cis-CH=CH; n is 2 or 3; X is halo, nitrato or PF6; and M is Au(I), Ag(I) or Cu(I); provided that when M is Cu(I), R -and R' are the same and are phenyl, and A is (CH2)2, X is other than halo or other than nitrato; and further provided that when R and R' are the same and are monosubstituted phenyl, M is other than.Cu(I); and further provided that when R and R' are the same and are ethyl, A is (CH2)2 and M is Au(I), X is other than halo; and further provided that when R and R' are the same and are phenyl, A is (CH2)2 and M is Au(I), X is other than chloro. 4. A compound according to any one of claims 1 to 3 wherein R and R' are the same and are phenyl, or Rl is ethyl when R is phenyl, A is the same and is (CH2)2, (CH2)3 or cis-CH=CH, M is Au (I) or Ag (I) and X is chloro or nitrato. 5. A compound according to claim 4 wherein R' is ethyl when R is phenyl, A is (CH2)2, M is Au(I), and X is chloro. 6. A compound according to claim 4 wherein R and R' are the same and are phenyl, M is Au(I), X is chloro, and A is - (CH2) -(CR2)3-, or cis-CH=CH-. 7. A compound according to claim 4 wherein R and IR' are the same and are phenyl, A is -(CR2)2-, M is Ag (I) and X is nitrato. 8.. A compound according to claim 4 wherein R and R' are the same and are phenyl, M is Au(I), A is -(CR2)2-, and X is chloro. 9. A compound the formula (II) according to either claim 1 or 2 wherein X is the same and is chloro. 10. A pharmaceutical composition which comprises a compound according to any one of claims 1 to 9 and a pharmaceutically acceptable carrier or diluent. 11. A composition according to claim 10 in which the composition is in dosage unit form adapted for parenteral administration. 12. A composition according to claim 11 in which the parenteral dosage unit is adapted to administer 5 mg to about 20 mg/m2 or body surface. Claims for Austria 1. A process for preparing a pharmaceutical composition which comprises admixing an inert pharmaceutically acceptable carrier or diluent with an effective tumor cell growth-inhibiting amount of an active ingredient, wherein said active ingredient is a compound of Formula (I) or Formula (IT): EMI34.1 Formula (I) wherein R and R' are the same and are phenyl, ethyl or monosubstituted phenyl wherein said substituent is halo, or R' is ethyl when R is phenyl; A is the same and is (CH2)n or cis-CH=CR; n is 2 or 3; X is halo, nitrato or PF6; and M is Au(I), Ag(I) or Cu(I) ; provided that when M is Cu(I), R and R' are the same and are phenyl, and A is (CR2)2, X is other than halo; and further provided that when R and R' are the same and are monosubstituted phenyl, M is other than Cu(I); and further provided that when R and R' are the same and are ethyl, A is (CH2)2 and M is Au(I), X is other than halo; EMI35.1 Formula (II) wherein W is the same and is phenyl; and X is the same and is halo or nitrato. 2. The process of Claim 1 in which the composition is in dosage unit form adapted for parenteral administration. 3. The process of Claim 2 in which the parenteral dosage unit is adapted to administer 5 mg to about 20 mg/m2 of body surface. 4. The process of Claim 1 wherein the active ingredient is a compound of Formula (I) and R and R' are the same and are phenyl, or R' is ethyl when R is phenyl, A is the same and is (CH2) 2, (CH3)3 or cis-CH=CR, M is Au(I) or Ag(I) and X is chloro or nitrato. 5. The process of Claim 4 wherein R' is ethyl when R is phenyl, A is (CR2)2, M is Au(I), and X is chloro. 6. The process of Claim 4 wherein R and R' are the same and are phenyl, A is (CR2)2, M is Au(I), and X is chloro. 7. The process of Claim 4 wherein R' and R are the same'and are phenyl, A is (CR2)2, M is Ag(I) and X is nitrato. 8. The process of Claim 4 wherein R and R' are the same and are phenyl, A is cis-CH=CR, M is au (I) and X is chloro. 9. The process of Claim 4 wherein R and R' are the same and are phenyl, A is (CH2)3, M is Au(I) and X is chloro. 10. The process of Claim 1 wherein the active ingredient is a compound of Formula (II) and X is the same and is chloro.

Inventors: BERNERS-PRICE, SUSAN JANE, JOHNSON, RANDALL KEITH, MIRABELLI, CHRISTOPHER KEVIN, SADLER, PETER JOHN
Applicants: SMITHKLINE BECKMAN CORPORATION
Application year: 1985
Main classification: C07F9
IPC codes: C07F9